Carcinoembryonic Antigen Market Research Report - Global Forecast till 2027

Carcinoembryonic Antigen Market Research Report: Information by Application (Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Lung Cancer, and Others), End User (Hospitals and Clinics, Diagnostic Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2027

ID: MRFR/Pharma/0288-HCR | February 2021 | Region: Global | 81 pages

Carcinoembryonic Antigen Market


The carcinoembryonic antigen market is expected to exhibit significant growth over the forecast period. The market was valued at approximately USD 2024.55 million in 2018 and is projected to register a 6.86% CAGR over the forecast period. Carcinoembryonic antigen is a glycoprotein of molecular weight of approximately 180 kD, which is present in normal fetal gastrointestinal tissue. It is usually present at very low concentrations in adults. However, the concentration can increase if the person is affected by any tumors and cancers. Therefore, the increasing prevalence rates of cancers such as colorectal cancer and pancreatic cancer is estimated to push the demand for precise diagnostics.

For instance, in 2018, the World Cancer Research Fund (WCRF) International mentioned in a published report that breast cancer was the most commonly occurring cancer in women and the second most common cancer. Breast cancer accounted for more than 2 million new cases in 2018 across the world. Additionally, the increasing number of companies entering this market is anticipated to drive the growth of the carcinoembryonic antigen market. However, the risk of infections associated with this type of testing, along with the inefficiency of diagnosing cancer at an early stage is likely to hamper the market growth.

Carcinoembryonic Antigen Market Segmentation

The carcinoembryonic antigen market has been segmented into application, end user, and region. Based on application, the market has been segmented into colorectal cancer, pancreatic cancer, breast cancer, lung cancer, and others. The market, by end user, has been segmented into hospitals and clinics, diagnostic centers, and others. The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified as France, Germany, Spain, the UK, Italy, and the rest of Western Europe.  The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in Middle East & Africa is divided into the Middle East and Africa.  

Key Players

Lee BioSolutions (US), F. Hoffmann-La Roche Ltd (Switzerland), Quest Diagnostics Incorporated (US), Genway Biotech, Inc. (US), RayBiotech, Inc. (US), Merck KGaA (Germany), Abcam plc (UK), Boster Biological Technology (US), Creative Diagnostics (US), and Laboratory Corporation of America Holdings (US) are some of the key players operating in the carcinoembryonic antigen market. 


Regional Market Summary Global Carcinoembryonic antigen Market Share (%), by Region, 2018


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports


Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the carcinoembryonic antigen market owing to the high prevalence of colorectal cancer. Europe is expected to hold the second-largest position in the market. The presence of a large patient population and established market players in the European countries fuel the market growth in this region. The World Health Organization (WHO) stated that breast cancer accounts for 28% of the total population in Europe. Asia-Pacific is expected to be the fastest-growing regional market owing to the growing initiatives by the public and private organizations. Private companies, as well as government organizations, are conducting campaigns to create awareness about the different types of cancers. The market in the Middle East & Africa holds the least share of the market due to the least amount of initiatives by public bodies.  

Market of Carcinoembryonic Antigen, by Application



  • Colorectal Cancer

  • Pancreatic Cancer

  • Breast Cancer

  • Lung Cancer

  • Others


Market of Carcinoembryonic Antigen, by End User



  • Hospitals and Clinics

  • Diagnostic Centers

  • Others


Market of Carcinoembryonic Antigen, by Region



  • Americas


    • North America

    • US

    • Canada

    • Latin America




  • Europe


    • Western Europe

    • Germany

    • France

    • Italy

    • Spain

    • UK

    • Rest of Western Europe

    • Eastern Europe




  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific




  • Middle East & Africa


    • Middle East

    • Africa



Intended Audience



  • Biotechnology companies

  • Pharmaceutical companies

  • Hospitals and clinics

  • Diagnostic centers

  • Academic institutes

  • Government organizations



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2018: USD 2024.55 Million
  • 2027: Significant Value
  •   CAGR   6.86% (2018-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Application and End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Lee BioSolutions (US), F. Hoffmann-La Roche Ltd (Switzerland), Quest Diagnostics Incorporated (US), Genway Biotech, Inc. (US), RayBiotech, Inc. (US), Merck KGaA (Germany), Abcam plc (UK), Boster Biological Technology (US), Creative Diagnostics (US), and Laboratory Corporation of America Holdings (US)
      Key Market Opportunities   risk of infections associated with this type of testing, along with the inefficiency of diagnosing cancer
      Key Market Drivers

  • Increasing prevalence of cancer
  • rising healthcare expenditures
  • developing diagnostic technologies


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    The valuation of Carcinoembryonic Antigen Market was USD 2024.55 million in 2018.

    The predicted CAGR of Carcinoembryonic Antigen Market would be 6.86% for the forecast period of 2019-2025.

    The segments of Carcinoembryonic Antigen Market are colorectal cancer, pancreatic cancer, breast cancer, lung cancer, and others.

    The segments of Carcinoembryonic Antigen Market are colorectal cancer, pancreatic cancer, breast cancer, lung cancer, and others.

    The end users segments are hospitals and clinics, diagnostic centers, and others.

    TABLE OF CONTENTS

    1. REPORT PROLOGUE

    2. MARKET INTRODUCTION

    2.1. Definition

    2.2. Scope of the Study

    2.2.1. Research Objective

    2.2.2. Assumptions

    2.2.3. Limitations

    3. RESEARCH METHODOLOGY

    3.1. Overview

    3.2. Primary Research

    3.3. Secondary Research

    3.4. Market Size Estimation

    4. MARKET DYNAMICS

    4.1. Overview

    4.2. Drivers

    4.3. Restraints

    4.4. Opportunities

    5. MARKET FACTOR ANALYSIS

    5.1. Porter’s Five Forces Analysis

    5.1.1. Bargaining Power of Suppliers

    5.1.2. Bargaining Power of Buyers

    5.1.3. Threat of New Entrants

    5.1.4. Threat of Substitutes

    5.1.5. Intensity of Rivalry

    5.2. Value Chain Analysis

    5.2.1. R&D and Designing

    5.2.2. Manufacturing

    5.2.3. Distribution & Sales

    5.2.4. Post Sales Services

    6. GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION

    6.1. Overview

    6.2. Colorectal Cancer

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3. Pancreatic Cancer

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.4. Breast Cancer

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.5. Lung Cancer

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.6. Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7. GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER

    7.1. Overview

    7.2. Hospitals and Clinics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3. Diagnostic Centers

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4. Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8. GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY REGION

    8.1. Overview

    8.2. Americas

    8.2.1. North America

    8.2.1.1. US

    8.2.1.2. Canada

    8.2.2. Latin America

    8.3. Europe

    8.3.1. Western Europe

    8.3.1.1. Germany

    8.3.1.2. France

    8.3.1.3. Italy

    8.3.1.4. Spain

    8.3.1.5. UK

    8.3.1.6. Rest of Western Europe

    8.3.2. Eastern Europe

    8.4. Asia-Pacific

    8.4.1. Japan

    8.4.2. China

    8.4.3. India

    8.4.4. Australia

    8.4.5. South Korea

    8.4.6. Rest of Asia-Pacific

    8.5. Middle East & Africa

    8.5.1. Middle East

    8.5.2. Africa

    9. COMPANY LANDSCAPE

    9.1. Overview

    9.2. Competitive Analysis

    9.3. Market Share Analysis

    9.4. Major Growth Strategy in the Global Carcinoembryonic Antigen Market

    9.5. Competitive Benchmarking

    9.6. Leading Players in Terms of Number of Developments in the Global Carcinoembryonic Antigen Market

    9.7. Key Developments and Growth Strategies

    9.7.1. New Product Launches

    9.7.2. Mergers and Acquisitions

    9.7.3. Joint Ventures

    9.8. Major Players Financial Matrix & Market Ratio

    9.8.1. Sales & Operating Income 2020

    9.8.2. Major Players R&D Expenditure 2020

    9.9. Major Players Capital Market Ratio

    10. COMPANY PROFILES

    10.1. Abcam plc

    10.1.1. Company Overview

    10.1.2. Product Overview

    10.1.3. Financial Overview

    10.1.4. Key Developments

    10.1.5. SWOT Analysis

    10.1.6. Key Strategies

    10.2. Boster Biological Technology

    10.3. Creative Diagnostics

    10.4. F. Hoffmann-La Roche Ltd

    10.5. Genway Biotech, Inc.

    10.6. Laboratory Corporation of America Holdings

    10.7. Lee BioSolutions

    10.8. Merck KGaA

    10.9. Quest Diagnostics Incorporated

    10.10. RayBiotech, Inc.

    10.11. Others

    11. APPENDIX

    11.1. References

    11.2. Related Reports


    LIST OF TABLES

    TABLE 1 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET SYNOPSIS, 2020-2027

    TABLE 2 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

    TABLE 3 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

    TABLE 4 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 5 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY REGION, 2020-2027 (USD MILLION)

    TABLE 6 NORTH AMERICA: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

    TABLE 7 NORTH AMERICA: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 8 US: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

    TABLE 9 US: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 10 CANADA: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

    TABLE 11 CANADA: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 12 LATIN AMERICA: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

    TABLE 13 LATIN AMERICA: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 14 EUROPE: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

    TABLE 15 EUROPE: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 16 WESTERN EUROPE: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

    TABLE 17 WESTERN EUROPE: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 18 EASTERN EUROPE: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

    TABLE 19 EASTERN EUROPE: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 20 ASIA-PACIFIC: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

    TABLE 21 ASIA-PACIFIC: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 22 MIDDLE EAST & AFRICA: CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

    TABLE 23 MIDDLE EAST & AFRICA: CARCINOEMBRYONIC ANTIGEN MARKET, BY END USER, 2020-2027 (USD MILLION)


    LIST OF FIGURES

    FIGURE 1 RESEARCH PROCESS

    FIGURE 2 MARKET STRUCTURE OF THE GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET

    FIGURE 3 MARKET DYNAMICS OF THE GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET

    FIGURE 4 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET SHARE, BY APPLICATION, 2020 (%)

    FIGURE 5 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET SHARE, BY END USER, 2020 (%)

    FIGURE 6 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 7 AMERICAS: CARCINOEMBRYONIC ANTIGEN MARKET SHARE BY REGION, 2020 (%)

    FIGURE 8 NORTH AMERICA: CARCINOEMBRYONIC ANTIGEN MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 9 EUROPE: CARCINOEMBRYONIC ANTIGEN MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 10 WESTERN EUROPE: CARCINOEMBRYONIC ANTIGEN MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 11 ASIA-PACIFIC: CARCINOEMBRYONIC ANTIGEN MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 12 MIDDLE EAST & AFRICA: CARCINOEMBRYONIC ANTIGEN MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 13 GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

    FIGURE 14 ABCAM PLC.: KEY FINANCIALS

    FIGURE 15 ABCAM PLC: SEGMENTAL REVENUE

    FIGURE 16 ABCAM PLC: REGIONAL REVENUE

    FIGURE 17 BOSTER BIOLOGICAL TECHNOLOGY: KEY FINANCIALS

    FIGURE 18 BOSTER BIOLOGICAL TECHNOLOGY: SEGMENTAL REVENUE

    FIGURE 19 BOSTER BIOLOGICAL TECHNOLOGY: REGIONAL REVENUE

    FIGURE 20 CREATIVE DIAGNOSTICS: KEY FINANCIALS

    FIGURE 21 CREATIVE DIAGNOSTICS: SEGMENTAL REVENUE

    FIGURE 22 CREATIVE DIAGNOSTICS: REGIONAL REVENUE

    FIGURE 23 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS

    FIGURE 24 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

    FIGURE 25 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE

    FIGURE 26 GENWAY BIOTECH, INC.: KEY FINANCIALS

    FIGURE 27 GENWAY BIOTECH, INC.: SEGMENTAL REVENUE

    FIGURE 28 GENWAY BIOTECH, INC.: REGIONAL REVENUE

    FIGURE 29 LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY FINANCIALS

    FIGURE 30 LABORATORY CORPORATION OF AMERICA HOLDINGS: SEGMENTAL REVENUE

    FIGURE 31 LABORATORY CORPORATION OF AMERICA HOLDINGS: REGIONAL REVENUE

    FIGURE 32 LEE BIOSOLUTIONS: KEY FINANCIALS

    FIGURE 33 LEE BIOSOLUTIONS: SEGMENTAL REVENUE

    FIGURE 34 LEE BIOSOLUTIONS: REGIONAL REVENUE

    FIGURE 35 MERCK KGAA: KEY FINANCIALS

    FIGURE 36 MERCK KGAA: SEGMENTAL REVENUE

    FIGURE 37 MERCK KGAA: REGIONAL REVENUE

    FIGURE 38 QUEST DIAGNOSTICS INCORPORATED: KEY FINANCIALS

    FIGURE 39 QUEST DIAGNOSTICS INCORPORATED: SEGMENTAL REVENUE

    FIGURE 40 QUEST DIAGNOSTICS INCORPORATED: REGIONAL REVENUE

    FIGURE 41 RAYBIOTECH, INC.: KEY FINANCIALS

    FIGURE 42 RAYBIOTECH, INC.: SEGMENTAL REVENUE

    FIGURE 43 RAYBIOTECH, INC.: REGIONAL REVENUE